Health Benefits and Molecular Mechanisms of Urolithin A: From a Gut Microbiota-Derived Metabolite to Translational Applications.
Level 5 - mechanism / opinion, no new human data
Narrative review summarizing preclinical mechanisms and preliminary human studies.
PubMed 42502809 · doi:10.1002/fsn3.72167
What was done
This review summarized evidence on urolithin A (a gut microbiota metabolite of ellagitannins and ellagic acid), covering its molecular mechanisms, preclinical disease models, individual microbiome-dependent bioavailability, and existing human clinical studies.
What was found
The abstract reports no quantitative data or effect sizes. It reports that urolithin A acts primarily via mitochondrial quality control, mitophagy, oxidative stress, and inflammatory pathways. Preclinical models show potential benefits across musculoskeletal, cardiovascular, neurological, and oncologic conditions, while human clinical evidence is described as preliminary, restricted to safety, tolerability, muscle function, exercise outcomes, and selected metabolic biomarkers.
Why it matters
It outlines the current translational status of urolithin A from cellular mitophagy pathways to early human trials, highlighting its potential role in precision nutrition for aging.
Limits
This is a narrative review with no formal systematic search methodology reported in the abstract. Clinical evidence in humans remains preliminary, limited in duration and scope, with broader disease-modifying claims supported only by in vitro and animal models.
Cited by
- supports Ellagitannins found in pomegranates, walnuts, and berries are converted by gut microbiota into urolithin A, which promotes the recycling of old mitochondria through mitophagy.